GBA1 and Parkinson disease: Based on these studies, a multicenter, randomized, double-blind clinical study was launched to determine the safety and efficacy of the GlcCer synthase inhibitor GZ/SAR402671 in PD patients with GBA mutations (clinicalTrials.gov identifier: NCT02906020).